Quantcast

Latest Neurocrine Biosciences Stories

2014-05-29 12:29:23

Live Audio Webcast will be on June 5, 2014 SAN DIEGO, May 29, 2014 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at the Jefferies 2014 Global Healthcare Conference in New York City. The live presentation takes place on Thursday, June 5 at 11:30am ET (8:30am PT). The presentation will be webcast and may be accessed on the Company's website at...

2014-05-08 12:30:07

Live Audio Webcast will be on May 15, 2014 SAN DIEGO, May 8, 2014 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at the Bank of America Merrill Lynch 2014 Health Care Conference in Las Vegas. The live presentation takes place on Thursday, May 15 at 10:40am PT (1:40pm ET). The presentation will be webcast and may be accessed on the Company's website...

2014-05-08 08:34:15

Editor Note: For more information about this release, please scroll to bottom. LONDON, May 8, 2014 /PRNewswire/ -- The trading session on Wednesday, May 07, 2014 ended on a mixed note as the Dow Jones Industrial Average finished at 16,518.54, up 0.72% and the NASDAQ Composite closed at 4,067.67, down 0.32%. The S&P 500 finished the day 0.56% higher at 1,878.21. During the trading session eight out of ten sectors finished on a higher note. The S&P 500 Health Care Sector...

2014-05-01 12:32:53

Live Audio Webcast will be on May 8, 2014 SAN DIEGO, May 1, 2014 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at Deutsche Bank's 39(th) Annual Health Care Conference in Boston. The live presentation takes place on Thursday, May 8 at 10:40am ET (7:40am PT). The presentation will be webcast and may be accessed on the Company's website at...

2014-04-30 16:30:22

-Endometriosis Phase III Violet Petal Study Completes Screening- SAN DIEGO, April 30, 2014 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced its financial results for the quarter ended March 31, 2014. For the first quarter of 2014, the Company reported a net loss of $11.8 million, or $0.17 loss per share, compared to a net loss of $12.1 million, or $0.18 loss per share, for the same period in 2013. The Company's balance sheet at March 31, 2014...

2014-04-25 16:24:05

Conference Call and Webcast Scheduled For Wednesday, April 30, 2014 SAN DIEGO, April 25, 2014 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that the Company will report its first quarter 2014 financial results after the Nasdaq market closes on Wednesday, April 30, 2014. Neurocrine will then host a live conference call and webcast to discuss its financial results and provide a Company update Wednesday afternoon, April 30, 2014 at 5:00 p.m. Eastern Time...

2014-03-04 16:25:14

Live Audio Webcast will be on March 11, 2014 SAN DIEGO, March 4, 2014 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at the 26(th) Annual Roth Conference in Laguna. The live presentation takes place on Tuesday, March 11 at 9:30am PT (12:30pm ET). The presentation will be webcast and may be accessed on the Company's website at...

2014-02-27 20:23:03

Live Audio Webcast will be on March 4, 2014 SAN DIEGO, Feb. 27, 2014 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at the Cowen and Company 34(th) Annual Health Care Conference in Boston. The live presentation takes place on Tuesday, March 4 at 9:20am ET (6:20am PT). The presentation will be webcast and may be accessed on the Company's website at...

2014-02-26 20:22:32

SAN DIEGO, Feb. 26, 2014 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the pricing of an underwritten public offering of 8,000,000 shares of its common stock at a price to the public of $17.75 per share. The gross proceeds to Neurocrine from this offering, before deducting underwriting discounts and commissions and other offering expenses payable by Neurocrine, are expected to be approximately $142 million. The offering is expected to close on or...

2014-02-25 16:29:29

SAN DIEGO, Feb. 25, 2014 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that it is offering to sell 7,000,000 shares of its common stock in an underwritten public offering. In connection with this offering, Neurocrine will also grant to the underwriters a 30-day option to purchase up to an additional 1,050,000 shares of common stock. Jefferies LLC and J.P. Morgan Securities LLC are acting as joint book-running managers for this offering. The offering is...


Word of the Day
mundungus
  • A stinking tobacco.
  • Offal; waste animal product; organic matter unfit for consumption.
This word comes from the Spanish 'mondongo,' tripe, entrails.